All authors: Institute of Cancer Research, London, United Kingdom.
J Clin Oncol. 2015 Feb 10;33(5):426-32. doi: 10.1200/JCO.2014.56.5689. Epub 2015 Jan 5.
Knowledge of the contribution of high-penetrance susceptibility to familial colorectal cancer (CRC) is relevant to the counseling, treatment, and surveillance of CRC patients and families.
To quantify the impact of germline mutation to familial CRC, we sequenced the mismatch repair genes (MMR) APC, MUTYH, and SMAD4/BMPR1A in 626 early-onset familial CRC cases ascertained through a population-based United Kingdom national registry. In addition, we evaluated the contribution of mutations in the exonuclease domain (exodom) of POLE and POLD1 genes that have recently been reported to confer CRC risk.
Overall mutations (pathogenic, likely pathogenic) in MMR genes make the highest contribution to familial CRC (10.9%). Mutations in the other established CRC genes account for 3.3% of cases. POLE/POLD1 exodom mutations were identified in three patients with family histories consistent with dominant transmission of CRC. Collectively, mutations in the known genes account for 14.2% of familial CRC (89 of 626 cases; 95% CI = 11.5, 17.2).
A genetic diagnosis is feasible in a high proportion of familial CRC. Mainstreaming such analysis in clinical practice should enable the medical management of patients and their families to be optimized. Findings suggest CRC screening of POLE and POLD1 mutation carriers should be comparable to that afforded to those at risk of HNPCC. Although the risk of CRC associated with unexplained familial CRC is in general moderate, in some families the risk is substantive and likely to be the consequence of unidentified genes, as exemplified by POLE and POLD1. Our findings have utility in the design of genetic analyses to identify such novel CRC risk genes.
了解高外显率遗传易感性对家族性结直肠癌(CRC)的贡献,有助于对 CRC 患者及其家族进行咨询、治疗和监测。
为了量化种系突变对家族性 CRC 的影响,我们对通过基于人群的英国国家注册处确定的 626 例早发性家族性 CRC 病例进行了错配修复基因(MMR)APC、MUTYH 和 SMAD4/BMPR1A 的测序。此外,我们评估了最近报道的具有 CRC 风险的外切酶结构域(exonodom)POLE 和 POLD1 基因突变的贡献。
总体而言,MMR 基因中的突变(致病性、可能致病性)对家族性 CRC 的贡献最大(10.9%)。其他已确立的 CRC 基因的突变占病例的 3.3%。在具有一致的 CRC 家族史的 3 名患者中发现了 POLE/POLD1 exonodom 突变,这些家族史提示 CRC 呈显性遗传。已知基因的突变共同导致 14.2%的家族性 CRC(626 例中的 89 例;95%CI=11.5,17.2)。
在很大一部分家族性 CRC 中可以进行基因诊断。在临床实践中推广这种分析应该能够优化患者及其家族的医疗管理。研究结果表明,对 POLE 和 POLD1 突变携带者的 CRC 筛查应与对 HNPCC 高危人群的筛查相当。虽然一般来说,与不明原因的家族性 CRC 相关的 CRC 风险适中,但在某些家族中,风险很大,可能是由于未识别的基因所致,POLE 和 POLD1 就是这种情况的例证。我们的研究结果对于设计基因分析以识别此类新的 CRC 风险基因具有实用性。